WithdrawnPhase 4

The Middle East Dual Anti-platelet Treatment in Acute Transient Ischemic Attack

Stopped: Could not get study started

Canada0Started 2014-07

Plain-language summary

The primary goal of the research is to determine if 10 days of dual anti-platelet treatment is as effective as 30 days of similar treatment in the prevention of stroke, myocardial ischemia (MI) and death in patients with TIAs and minor stroke.

Who can participate

SexALL

See this in plain English?

AI-rewrites the medical criteria so a patient or caregiver can understand them. Always confirm with the trial site.

Inclusion criteria

✓. Neurologic deficit (based on history or exam) attributed to focal brain ischemia and EITHER:
✓. Ability to randomize within 24 hours of time last known free of new ischemic symptoms.
✓. Head CT or MRI ruling out hemorrhage or other pathology, such as vascular malformation, tumor, or abscess, that could explain symptoms or contraindicate therapy.
✓. Ability to tolerate aspirin at a dose of 50-325 mg/day.

Exclusion criteria

✕. TIA symptoms limited to isolated numbness, isolated visual changes, or isolated dizziness/vertigo.
✕. In the judgment of the treating physician, a candidate for thrombolysis, endarterectomy or endovascular intervention, unless the subject declines both endarterectomy and endovascular intervention at the time of the evaluation for eligibility.
✕. Receipt of any intravenous or intra-arterial thrombolysis within 1 week prior to index event.
✕. Gastrointestinal bleed or major surgery within 3 months prior to index event. History of non-traumatic intracranial hemorrhage.
✕. Clear indication for anticoagulation (e.g., warfarin, heparin) anticipated during the study period (atrial fibrillation, mechanical heart valve, deep venous thrombosis, pulmonary embolism, antiphospholipid antibody syndrome, hypercoagulable state).
✕. Qualifying ischemic event induced by angiography or surgery.
✕. Severe non-cardiovascular comorbidity with life expectancy \<3 months.
✕. Contraindication to clopidogrel or aspirin:

What they're measuring

To test if 10 days of treatment with ASA and Clopidogrel has fewer complications than 30 days of similar treatment

Timeframe: 4 years prospective study

What is the feasibility and efficacy of the non-inferiority design

Timeframe: 4 years

Trial details

NCT IDNCT02144831

SponsorUniversity of Alberta

Sponsor typeOTHER

Study typeINTERVENTIONAL

Primary completion2018-06

View on ClinicalTrials.gov More Transient Ischemic Attacks trials